Navigation Links
Boston Scientific Announces Settlement of DOJ Investigation Relating to Post-Market Surveys Conducted By Guidant
Date:12/23/2009

NATICK, Mass., Dec. 23 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a civil settlement with the U.S. Department of Justice regarding the Department's investigation relating to certain post-market surveys conducted by Guidant Corporation before Boston Scientific acquired Guidant in 2006. Boston Scientific had previously disclosed the investigation, which was conducted by the United States Attorney's office in Boston.

This civil settlement brings to a conclusion an investigation that began in 2005 and involves no admission of wrong doing by the Company. Under the terms of the settlement, the Company has agreed to pay $22 million, which was previously fully accrued.

The Company also agreed to enter into a Corporate Integrity Agreement (CIA) with the Office of Inspector General for the U.S. Department of Health and Human Services. The CIA requires enhancements to certain compliance procedures related to financial arrangements with health care providers. It is limited to the Company's cardiac rhythm management business, which became part of Boston Scientific through the Guidant acquisition.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding resolution of government proceedings, compliance procedures, financial arrangements with health care providers and product performance. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements. This cautionary statement is applicable to all forward-looking statements contained in this document.


    CONTACT: Paul Donovan
             508-650-8541 (office)
             508-667-5165 (mobile)
             Media Relations
             Boston Scientific Corporation

             Larry Neumann
             508-650-8696 (office)
             Investor Relations
             Boston Scientific Corporation

SOURCE Boston Scientific Corporation


'/>"/>
SOURCE Boston Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Boston Scientific Announces Election of Nelda Connors to Its Board of Directors
2. Boston Scientific Announces Pricing of $2 Billion of Senior Notes
3. Regeneron Announces Presentation at the Deutsche Bank 2009 Biotech Boston Confab
4. Boston Scientific to Participate in Piper Jaffray Health Care Conference
5. Boston Scientific Announces FDA Clearance and CE Mark for WallFlex(R) Fully Covered Esophageal Stent
6. Boston Scientific Announces Sponsorship of World Diabetes Day Campaign 2009
7. Boston Scientifics Urology/Gynecology Products Featured in Studies at Global Congress
8. Boston Scientifics Most Advanced Devices to Treat Heart Failure and Sudden Cardiac Death Now Available in Japan
9. Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation of Guidant
10. Boston Medical Center Managing H1N1 Flu Vaccination for its Community with Carefxs New Immunization Management Solution
11. Boston Scientific Announces Results for Third Quarter Ended September 30, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... , May 5, 2017   Provista , a proven ... than 200,000 customers, today announced Jim Cunniff as ... of executive and business experience to Provista, including most recently ... in California . He assumed his new ... is a great fit for Provista," says Jody Hatcher ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)... May 4, 2017  A new tight-tolerance microextrusion ... other highly-engineered materials, is being launched by Natvar, ... been developed in recent years to service a ... surgical applications. More expensive materials such as glass ... tubing due to their ability to consistently hold ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... , ... Amir Qureshi, MD is the first physician in Arkansas to implant ... The Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for ... to introduce the most powerful SCS system and the only stretchable lead on the ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community health data ... are located in the Midwest. With the average cost of healthcare rising and the ... with both the quality and affordability of where they live. An annual 2017 report ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating is proud to ... task chair specifically designed for clinical areas. Genie Copper Mesh is a crossover ... Cupron® to provide customers with a game changing chair that is affordably priced,” ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original campaign ... crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget to ... fidget toy to the market that was made of superior quality and wouldn’t break ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Silver Birch ... community, which is located on more than four acres of land at 5620 Sohl ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of ...
Breaking Medicine News(10 mins):